As I wrote on SH:

“Bioasis has a technology designed to deliver therapeutic candidates across the blood-brain barrier that we found interesting. Our 2019 agreement included an option right to acquire certain royalty rights on the next two license agreements entered into by Bioasis. We are pleased that Chiesi Group, a well-respected pharmaceutical company, is driving the development efforts of these enzymes in rare disease indications and to be able to acquire an economic position in them,” commented Jim Neal, Chief Executive Officer of XOMA.

Wtf was that option, I've never seen it anywhere (in financials or reports). Thats an awful deal to make. I'm wondering if that's why Mark Day was fired from the company. Cool validation and thanks for the 1.2M, but I've would've kept the full royalty and milestone payments.